Although serum levels of Gal-9 were demonstrated to be a promising marker to assess the IFN signature, our data suggest that Gal-9 could be a biomarker for SLE disease activity or particular SLE-related organ involvement. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.